We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Merck Drops Late-Stage Cancer Drug Trial Due to Disappointing Efficacy
Merck Drops Late-Stage Cancer Drug Trial Due to Disappointing Efficacy
Merck announced that it is ending a phase 3 study evaluating its immunotherapy bintrafusp alfa in patients with stage IV non-small-cell lung cancer, following disappointing efficacy results.